Policy | 09 August 2021
China NMPA approves phase II clinical trial of ASC40
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
CDSCO to fast-track trials and approval for COVID19 vaccine
The data should be submitted by August 12th 2021
Arch Pharma Labs has filed the application
Five seats reserved for Wards of COVID warriors in central MBBS admission
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
The highest reduction in prices for Pulse Oximeters, Blood Pressure Monitoring Machine and Nebulizer has been reported by importers
The govt has rolled out three schemes for promoting the manufacture of API
Drug formulations and biologics make impressive gains
The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
The GMP certificate is valid for three years until April 2024.
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Essential medicines were made available to more than 150 countries around the world during the pandemic
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
